
SITE INFORMATION FORM (PHASE I)

As part of the requirements for Ethics Approval, CSERB must be assured that the Investigator, who is legally responsible for the conduct of the research, has sufficient resources (ICH E.6 4.) to manage all responsibilities assigned as part of the study, including the protection of the trial participants. In addition, the Investigator must be able to personally oversee the proposed research (21 CFR 56.102 (b)).

Information on this document:

New Information:

Updated Information:

Previously Submitted:

The following information is correct and complete as of:

____/____/____
DD MMM YYYY

PROTOCOL INFORMATION

Sponsor/CRO name: _____

Study medication/device name: _____

Project name/code number: _____

Study/protocol number: _____

Study/protocol version number and date: (dd/MMM/yy): _____

Study/protocol title: _____

STAFF INFORMATION

Investigator name: _____ Tel: _____

Fax: _____

Investigator name: _____ Tel: _____

Fax: _____

Investigator name: _____ Tel: _____

Fax: _____

Secretary name: _____ Tel: _____

Fax: _____

Research nurse name: _____ Tel: _____

Fax: _____

Pharmacist name: _____ Tel: _____

Fax: _____

Clinical laboratory head name: _____ Tel: _____

Fax: _____

SITE INFORMATION

Study site address: (where study subjects are treated): _____

Name of clinical laboratory: _____

Location (address) of clinical laboratory: _____

Location (address) of pharmacy: _____

Location (address) of pharmacy: _____

Location of medical records department: _____

Location of storage area for CRFs: _____

Study facilities and equipment:

· Access to public transport; Yes No NA Comment
Specify: _____

· Proximity to a general hospital with emergency room; Yes No NA Comment
Specify: _____

· Capability for specialised studies (eg radio-labelled studies); Yes No NA Comment
Specify: _____

· Environmental control maintenance (eg temperature and light); Yes No NA Comment
Specify: _____

· Backup storage area for specimens in case of power loss; Yes No NA Comment
Specify: _____

· Disaster recovery scheme; Yes No NA Comment
Specify: _____

· Alert system for disaster; Yes No NA Comment
Specify: _____

· Inventory control procedures; Yes No NA Comment
Specify: _____

· SOPs; Yes No NA Comment
Specify: _____

· Documentation of computer validation; Yes No NA Comment

Specify: _____

· **Safety and emergency equipment and procedures:**

Emergency medication supplies; Yes No NA Comment

Specify: _____

Oxygen; Yes No NA Comment

Specify: _____

Suction; Yes No NA Comment

Specify: _____

Defibrillator with ECG monitor; Yes No NA Comment

Specify: _____

Continuous ECG monitors with arrhythmia detection; Yes No NA Comment

Specify: _____

Endotracheal tubes; Yes No NA Comment

Specify: _____

Stretchers; Yes No NA Comment

Specify: _____

Wheelchairs; Yes No NA Comment

Specify: _____

Pumps for IV administration; Yes No NA Comment

Specify: _____

· Alarm system to locate the sites of emergencies; Yes No NA Comment

Specify: _____

· Centrifuge; Yes No NA Comment

Specify: _____

· Refrigerators; Yes No NA Comment

Specify: _____

· Freezers; Yes No NA Comment

- Specify: _____
- Adequate space (eg offices, wards, archives); Yes No NA Comment
Specify: _____
 - Ability to perform analyses at night or during weekends; Yes No NA Comment
Specify: _____
 - Facilities for handling and storage (long-term) of biological samples; Yes No NA Comment
Specify: _____
 - Rooms for pharmacodynamic measurements; Yes No NA Comment
Specify: _____
 - Central clock in study rooms; Yes No NA Comment
Specify: _____
 - Cleaning facilities; Yes No NA Comment
Specify: _____
 - Computerised data management system to control sample movement; Yes No NA Comment
Specify: _____
 - Facilities to prepare labels for tubes; Yes No NA Comment
Specify: _____
 - Facilities for leisure activities; Yes No NA Comment
Specify: _____
 - Screening rooms; Yes No NA Comment
Specify: _____
 - Showers and toilets; Yes No NA Comment
Specify: _____
 - Laboratory rooms; Yes No NA Comment
Specify: _____
 - Kitchen for supply of standardised meals; Yes No NA Comment

Specify: _____

- Adequate number of beds (typically 12); Yes No NA Comment

Specify: _____

- Data entry procedures (eg direct, electronic); Yes No NA Comment

Specify: _____

- Capability for electronic data transfer; Yes No NA Comment

Specify: _____

Study site personnel:

- Staff with experience in clinical pharmacology and pharmacokinetics; Yes No NA Comment

- Staff with experience in venipuncture; Yes No NA Comment

- Staff with experience in diets and standardised meals; Yes No NA Comment

- Staff with technical experience to handle biological samples; Yes No NA Comment

- Staff with experience in drug-of-abuse testing; Yes No NA Comment

- Staff with experience in resuscitation; Yes No NA Comment

- Staff with experience in use of emergency equipment; Yes No NA Comment

- Qualified pharmacist for dispensing the study medication/device; Yes No NA Comment

Study subject population:

- Adequate source of healthy volunteers; Yes No NA Comment

Specify: _____

- Sufficiently large volunteer panel; Yes No NA Comment

Specify: _____

- Access to special populations: Yes No NA Comment

- Elderly; Yes No NA Comment

- Postmenopausal women; Yes No NA Comment

- Renally-impaired individuals; Yes No NA Comment

- Hepatically-impaired individuals; Yes No NA Comment
- Specify any other populations: _____
- Procedures to inform primary care physicians of study participation; Yes No NA Comment

CONTACT INFORMATION AND PARTICIPANT REIMBURSEMENT

Contact information to be listed in Informed Consent Form (for questions about the study):

Name: _____

Phone number: _____

Contact information for use in case of a research-related injury:

Name: _____

Phone number: _____

REIMBURSEMENT

Subjects will be reimbursed as follows: _____

CONFIRMATION OF INFORMATION

Printed or Typed Name of Person Completing This Form

I certify that the information contained above is accurate. I acknowledge Canadian SHIELD Ethics Review Board has the authority to oversee this study and suspend the study if necessary to protect the rights and welfare of the study participants. I agree to provide Canadian SHIELD Ethics Review Board with the information they require to conduct initial and continuing review of this study on a timely basis and that if the information is not provided, Canadian SHIELD may suspend the study.

Signature

Date

(____) _____

Phone number

Information to be filled in by Canadian SHIELD Ethics Review Board:

Protocol Tracking No.: _____

Protocol No.: _____

Sponsor: _____

Date of Protocol: _____

Date Presented to Board: _____

Date Received: _____